| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910865232203321 |
|
|
Autore |
Schatten Heide |
|
|
Titolo |
Cell and Molecular Biology of Ovarian Cancer : Updates, Insights and New Frontiers |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham : , : Springer International Publishing AG, , 2024 |
|
©2024 |
|
|
|
|
|
|
|
|
|
ISBN |
|
9783031583117 |
9783031583100 |
|
|
|
|
|
|
|
|
Edizione |
[1st ed.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (133 pages) |
|
|
|
|
|
|
Collana |
|
Advances in Experimental Medicine and Biology Series ; ; v.1452 |
|
|
|
|
|
|
Soggetti |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Intro -- Preface -- Contents -- 1: Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy -- 1.1 Microtubules -- 1.1.1 Formation and Features -- 1.1.2 Role in Cellular Function -- 1.2 NCCN-Approved Agents for Use in Ovarian Cancer -- 1.3 Microtubule-Stabilizing Agents -- 1.3.1 Paclitaxel -- 1.3.2 Nab-paclitaxel -- 1.3.3 Docetaxel -- 1.3.4 Ixabepilone -- 1.4 Microtubule-Destabilizing Agents -- 1.4.1 Vincristine -- 1.4.1.1 Vinblastine -- 1.4.2 Vinorelbine -- 1.5 Mechanisms of Resistance -- References -- 2: Tubulin Complexity in Cancer and Metastasis -- 2.1 Tubulin Complexity -- 2.2 Microtubule-Associated Proteins (MAPs) -- 2.3 Tubulin Posttranslational Modifications (PTMs) -- 2.4 Microtentacles -- References -- 3: The Impact of Centrosome Pathologies on Ovarian Cancer Development and Progression with a Focus on Centrosomes as Therapeutic Target -- 3.1 Introduction -- 3.2 Structure, Composition, and Function of Centrosomes and Abnormalities/Dysregulation in Ovarian Cancer -- 3.3 Centrosome Regulation in Normal Cell Cycles -- 3.4 Centrosome Dysregulation, Abnormalities in Ovarian Cancer, and New Research to Correct Centrosome Abnormalities -- 3.4.1 Centrosome Clustering -- 3.5 The Role of Primary Cilia in Ovarian Cancer -- 3.6 Centrosomes as Target for Ovarian Cancer Therapy -- 3.7 Conclusion and Future Directions -- |
|
|
|
|
|
|
|
|
|
References -- 4: Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives -- 4.1 Introduction to Epithelial Ovarian Cancer and Its Subtypes -- 4.1.1 Type I Neoplasms -- 4.1.1.1 Low-Grade Serous Ovarian Cancer (LGSOC) Subtype -- 4.1.1.2 Sero-mucinous Subtype -- 4.1.1.3 Mucinous Ovarian Carcinomas (MOC) -- 4.1.1.4 Endometrioid Ovarian Carcinomas (EEOC) -- 4.1.1.5 Clear Cell Ovarian Carcinomas (CCOC) -- 4.1.1.6 Brenner Tumours. |
4.1.2 Type II Neoplasms -- 4.1.2.1 High-Grade Serous Ovarian Cancer (HGSOC) -- 4.1.2.2 High Grade EEOC -- 4.1.2.3 Undifferentiated Carcinoma -- 4.2 Current Diagnostic Strategies -- 4.3 Current Treatment Modalities -- 4.3.1 Targeted Therapy -- 4.4 Resistance, a Major Limitation Against Currently Available Therapeutics -- 4.5 Elucidating Drug Resistance Mechanisms: Understanding the Molecular Players -- 4.5.1 Decreased Intracellular Drug Accumulation and Increased Drug Export -- 4.5.1.1 Influx Transporters -- 4.5.1.2 Efflux Transporters -- 4.5.2 Increased Drug Inactivation -- 4.5.2.1 CYP System -- 4.5.2.2 Glutathione S-Transferase (GST) -- 4.5.2.3 Uridine Diphospho-glucuronosyltransferase (UGT) Superfamily -- 4.5.3 Resistance to PARP Inhibitors and HR Pathways -- 4.5.4 Deregulated Autophagy -- 4.5.5 Altered Metabolism -- 4.5.5.1 Glucose Metabolism -- 4.5.5.2 Fatty Acid Metabolism -- 4.5.5.3 Altered Glutamine Metabolism -- 4.5.6 Evasion of Apoptosis -- 4.5.7 Cancer Stem Cells -- 4.5.8 Role of miRNAs and lncRNA -- 4.6 An Insight Into the Upcoming Therapies and Clinical Trials -- 4.6.1 Overcoming Bevacizumab Resistance Through Peptide Fusion Protein Trebananib -- 4.6.2 Emerging Targeted Therapies -- 4.6.2.1 Anti-angiogenic agents -- 4.6.2.2 Targeting the DNA Repair Pathway -- 4.6.2.3 Receptor Tyrosine Kinase Inhibitors -- 4.6.2.4 Epidermal Growth Factor Receptor- Family Targeted Inhibitors -- 4.6.2.5 MEK Inhibitors -- 4.6.2.6 PI3K Inhibitors -- 4.6.3 Strategies to Develop Additional Synthetic Lethal Therapies -- 4.6.3.1 Wee1 Inhibition -- 4.6.3.2 CHK1 Inhibitors -- 4.6.4 Sequential and Combinatorial Approaches Using Chemotherapeutics and Molecular Targeted Agents -- 4.6.5 Targeting Immune Evasion Mechanisms -- 4.6.5.1 Adoptive T-Cell Therapies -- 4.6.6 Targeting the Tumour Microenvironment. |
4.6.7 Vaccine-Based Therapies -- 4.6.7.1 Cell-Based Vaccine-Cvac -- 4.6.7.2 p53 Vaccine-p53MVA -- 4.6.7.3 Tumour-Associated Antigens-DPX-Survivac -- 4.7 Conclusion -- References -- 5: The Role of the Human Microbiome in Epithelial Ovarian Cancer -- 5.1 Introduction -- 5.2 Human Microbiome -- 5.3 Epithelial Ovarian Cancer and the Human Microbiome -- 5.3.1 Lower Reproductive Tract -- 5.3.2 Upper Reproductive Tract -- 5.3.3 Gastrointestinal Tract -- 5.4 Conclusions and Future Directions -- References -- 6: Insights into the Microbial Composition of Intratumoral, Reproductive Tract, and Gut Microbiota in Ovarian Cancer Patients -- 6.1 Introduction -- 6.2 Overview of Ovarian Cancer Associated Microbiota -- 6.2.1 Ovarian Cancer Tissue Microbial Composition and Origin -- 6.2.2 Reproductive Tract Microbial Composition -- 6.2.3 The Relationship Between Reproductive Tract Microbiota and Ovarian Cancer -- 6.2.4 Gut Microbiota in Ovarian Cancer Patients and Animal Models -- 6.3 Functions of Ovarian Cancer-Associated Microbiota Metabolites -- 6.3.1 Microbial Metabolites Affect Ovarian Cancer Development -- 6.3.2 Microbiota Affect Hormone Regulation and Carcinogenesis -- 6.3.3 Microbiota Regulate Inflammatory and Immune Regulation -- 6.4 Bacteria in Therapeutics and Diagnostics of Ovarian Cancer -- 6.4.1 The Role of Microbiota in Therapeutic Effects in Ovarian Cancer -- 6.4.1.1 The Potential Role of Microbiota in Ovarian Cancer Therapy Drug Resistance -- 6.4.1.2 A Dual Role of Antibiotic Therapy |
|
|
|
|
|
|
|
|
for Ovarian Cancer -- 6.4.2 Nutrient and Diet Modify Microbiome and Help Prevent Ovarian Cancer -- 6.5 Conclusion and Future Perspectives -- References -- 7: The Impact of Mitochondria in Ovarian Cancer Cell Metabolism, Proliferation, and Metastasis -- 7.1 Introduction -- 7.1.1 Mitochondrial Vulnerabilities Underlying Dysfunction and Disease. |
7.1.2 Mitochondrial Dysfunction in Ovarian Cancer -- 7.1.3 Present Treatment Difficulties for Ovarian Cancer and New Potential Treatment Strategies to Target Ovarian Cancer Mitochondrial Metabolism -- 7.1.4 Biobehavioral Factors Influencing Ovarian Cancer Development -- 7.2 Conclusions and Future Perspectives -- References -- Index. |
|
|
|
|
|
| |